Interpretation and use of FRAX in clinical practice

Kanis, J. A.; Hans, D.; Cooper, C.; Baim, S.; Bilezikian, J. P.; Binkley, N.; Cauley, J. A.; Compston, J. E.; Dawson-Hughes, B.; El-Hajj Fuleihan, G.; Johansson, H.; Leslie, W. D.; Lewiecki, E. M.; Luckey, M.; Oden, A.; Papapoulos, S. E.; Poiana, C.; Rizzoli, R.; Wahl, D. A.; McCloskey, E. V.

Affiliations

¹WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK

²Center of Bone Diseases, Bone and Joint Department, Lausanne University Hospital, Lausanne, Switzerland

³MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK

⁴NIHR Musculoskeletal Biomedical Research Unit, Institute of Musculoskeletal Sciences, University of Oxford, Oxford, UK

⁵Division of Endocrinology, University of Miami, Miller School of Medicine, Coral Gables, USA

⁶Columbia University College of Physicians and Surgeons, New York, USA

⁷Osteoporosis Clinical Research Program, University of Wisconsin, Madison, USA

⁸Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, USA

⁹Department of Medicine, Addenbrooke’s Hospital, Cambridge University, Cambridge, UK

¹⁰Jean Mayer United States Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, USA

¹¹WHO Collaborating Center for Metabolic Bone Disorders, American University of Beirut, Beirut, Lebanon

¹²Centre for Bone Research at the Sahlgrenska Academy, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden

¹³University of Manitoba, Winnipeg, Canada

¹⁴New Mexico Clinical Research & Osteoporosis Center, University of New Mexico School of Medicine, Albuquerque, USA

¹⁵St. Barnabas Osteoporosis & Metabolic Bone Disease Center, Livingston, USA

¹⁶Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, the Netherlands

¹⁷Department of Endocrinology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

¹⁸Division of Bone Diseases, Department of Rehabilitation and Geriatrics, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland

¹⁹International Osteoporosis Foundation, Nyon, Switzerland

²⁰Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK

Abstract and keywords

Summary: The introduction of the WHO FRAX® algorithms has facilitated the assessment of fracture risk on the basis of fracture probability. Its use in fracture risk prediction has strengths, but also limitations of which the clinician should be aware and are the focus of this review

Introduction: The International Osteoporosis Foundation (IOF) and the International Society for Clinical Densitometry (ISCD) appointed a joint Task Force to develop resource documents in order to make recommendations on how to improve FRAX and better inform clinicians who use FRAX. The Task Force met in November 2010 for 3 days to discuss these topics which form the focus of this review.

Methods: This study reviews the resource documents and joint position statements of ISCD and IOF.

Results: Details on the clinical risk factors currently used in FRAX are provided, and the reasons for the exclusion of others are provided. Recommendations are made for the development of surrogate models where country-specific FRAX models are not available.

Conclusions: The wish list of clinicians for the modulation of FRAX is large, but in many instances, these wishes cannot presently be fulfilled; however, an explanation and understanding of the reasons may be helpful in translating the information provided by FRAX into clinical practice.

Keywords: Bone mineral density; Clinical risk factors; Fracture probability; Risk assessment

Links

DOI: 10.1007/s00198-011-1713-z

PubMed: 21779818

WoS: 000293636500001

History

Received: 2011-05-18

Accepted: 2011-06-07

Online: 2011-07-21

Cited Works (25)

Year	Entry
2011	Cooper C, Cole ZA, Holroyd CR, Earl SC, Harvey NC, Dennison EM, Melton LJ, Cummings SR, Kanis JA; IOF CSA Working Group on Fracture Epidemiology. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int. May 2011;22(5):1277-1288.
2005	Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman JA, Pols H, Tenenhouse A. Alcohol intake as a risk factor for fracture. Osteoporos Int. July 2005;16(7):737-742.
2002	Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby AK. International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res. July 2002;17(7):1237-1244.
1998	Singer BR, McLauchlan GJ, Robinson CM, Christie J. Epidemiology of fractures in 15 000 adults: the influence of age and gender. J Bone Joint Surg. March 1998;80B(2):243-248.
2008	Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ III, Khaltaev N. A reference standard for the description of osteoporosis. Bone. March 2008;42(3):467-475.
2003	Stone KL, Seeley DG, Lui L-Y, Cauley JA, Ensrud K, Browner WS, Nevitt MC, Cummings SR; The Study of Osteoporotic Fractures research group. BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures. J Bone Miner Res. November 2003;18(11):1947-1954.
1999	Black DM, Arden NK, Palermo L, Pearson J, Cummings SR; Study of Osteoporotic Fractures Research Group. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. J Bone Miner Res. May 1999;14(5):821-828.
1998	Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC Jr, Lindsay R. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998;8(5):468-489.
2008	Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A. Case finding for the management of osteoporosis with FRAX^®: assessment and intervention thresholds for the UK. Osteoporos Int. October 2008;19(10):1395-1408.
2008	Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster J-Y, Borgstrom F, Rizzoli R; European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. April 2008;19(4):399-428.
2011	Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA; OF-IFCC Bone Marker Standards Working Group. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. February 2011;22(2):391-420.
1995	Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM; Study of Osteoporotic Fractures Research Group. Risk factors for hip fracture in white women. NEJM. March 23, 1995;332(12):767-773.
2008	Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int. October 2008;19(10):1431-1444.
2000	Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. June 2000;15(6):993-1000.
2003	Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone. October 2003;33(4):522-532.
2004	Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton LJ III, Tenenhouse A, Reeve J, Silman AJ, Pols HAP, Eisman JA, McCloskey EV, Mellstrom D. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. June 2004;19(6):893-899.
2001	McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Wasnich RD, Greenwald M, Kaufman J-M, Chesnut CH, Reginster J-Y; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group. NEJM. February 1, 2001;344(5):333-340.
2009	Kanis JA, Oden A, Johansson H, Borgström F, Ström O, McCloskey E. FRAX^® and its applications to clinical practice. Bone. May 2009;44(5):734-743.
2008	Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int. April 2008;19(4):385-397.
1996	Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. May 18, 1996;312(7041):1254-1259.
1997	Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. September 1997;7(5):407-413.
2005	Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ III, O'Neill T, Pols H, Reeve J, Silman A, Tenenhouse A. Predictive value of BMD for hip and other fractures. J Bone Miner Res. July 2005;20(7):1185-1194.
1999	Melton LJ III, Crowson CS, O’Fallon WM. Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int. January 1999;9(1):29-37.
2010	Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD; Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. Can Med Assoc J. November 23, 2010;182(17):1864-1873.
2007	Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Glüer C, Goltzman D, Hans D, Krieg M-A, La Croix A, McCloskey E, Mellstrom D, Melton LJ, Pols H, Reeve J, Sanders K, Schott A-M, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. August 2007;18(8):1033-1046.

Cited By (32)

Year	Entry
2016	Kanis JA, Harvey NC, Cooper C, Johansson H, Odén A, McCloskey EV; The Advisory Board of the National Osteoporosis Guideline Group. A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. December 2016;11(1):25.
2018	Trajanoska K, Morris JA, Oei L, Zheng H-F, Evans DM, Kiel DP, Ohlsson C, Richards JB, Rivadeneira F; GEFOS/GENOMOS consortium; 23andMe research team. Assessment of the genetic and clinical determinants of fracture risk: genome wide association and mendelian randomisation study. BMJ. August 29, 2018;362:k3225.
2017	Curtis EM, Moon RJ, Harvey NC, Cooper C. The impact of fragility fracture and approaches to osteoporosis risk assessment worldwide. Bone. November 2017;104:29-38.
2020	Rajapakse CS, Farid AR, Kargilis DC, Jones BC, Lee JS, Johncola AJ, Batzdorf AS, Shetye SS, Hast MW, Chang G. MRI-based assessment of proximal femur strength compared to mechanical testing. Bone. April 2020;133:115227.
2021	Champakanath A, Keshawarz A, Pyle L, Snell-Bergeon JK, Shah VN. Fracture risk assessment (FRAX) without BMD and risk of major osteoporotic fractures in adults with type 1 diabetes. Bone. February 2021;143:115614.
2021	Shah VN, Pyle L, Snell-Bergeon JK. Response to authors' concern. Bone. February 2021;143:115750.
2023	Alajlouni DA, Bliuc D, Tran TS, Blank RD, Center JR. Muscle strength and physical performance contribute to and improve fracture risk prediction in older people: a narrative review. Bone. July 2023;172:116755.
2020	Lee SH, Lee JY, Lim K-H, Lee Y-S, Kim S-H, Choi S, Cho S-H, Koh J-M. High circulating sphingosine 1-phosphate is a risk factor for osteoporotic fracture independent of fracture risk assessment tool. Calcif Tiss Int. October 2020;107(4):362-370.
2016	Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis — 2016. Endocr Pract. September 1, 2016;22(suppl 4):1-42.
2020	Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa SJ, Watts NB. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis: 2020 update. Endocr Pract. May 2020;26(suppl 1):1-46.
2021	Harvey NC, Kanis JA, Liu E, Cooper C, Lorentzon M, Bea JW, Carbone L, Cespedes Feliciano EM, Laddu DR, Schnatz PF, Shadyab AH, Stefanick ML, Wactawski‐Wende J, Crandall CJ, Johansson H, McCloskey E. Predictive value of DXA appendicular lean mass for incident fractures, falls, and mortality, independent of prior falls, FRAX, and BMD: findings from the Women's Health Initiative (WHI). J Bone Miner Res. April 2021;36(4):654-661.
2022	Alajlouni D, Tran T, Bliuc D, Blank RD, Cawthon PM, Orwoll ES, Center JR. Muscle strength and physical performance improve fracture risk prediction beyond Garvan and FRAX: the Osteoporotic Fractures in Men (MrOS) Study. J Bone Miner Res. March 2022;37(3):411-419.
2017	Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or alendronate for fracture prevention in women with osteoporosis. NEJM. October 12, 2017;377(15):1417-1427.
2013	Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO); Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. January 2013;24(1):23-57.
2018	Harvey NC, Odén A, Orwoll E, Lapidus J, Kwok T, Karlsson MK, Rosengren BE, Ribom E, Cooper C, Cawthon PM, Kanis JA, Ohlsson C, Mellström D, Johansson H, McCloskey E. Measures of physical performance and muscle strength as predictors of fracture risk independent of FRAX, falls, and aBMD: a meta-analysis of the osteoporotic fractures in men (MrOS) study. J Bone Miner Res. December 2018;33(12):2150-2157.
2019	Kanis JA, Cooper C, Rizzoli R, Reginster J-Y; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO); Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. January 2019;30(1):3-44.
2020	Löffler MT, Sollmann N, Mei K, Valentinitsch A, Noël PB, Kirschke JS, Baum T. X-ray-based quantitative osteoporosis imaging at the spine. Osteoporos Int. February 2020;31(2):233-250.
2020	Lau EMC, Dinavahi R, Woo YC, Wu C-H, Guan J, Maddox J, Tolman C, Yang W, Shin CS. Romosozumab or alendronate for fracture prevention in East Asian patients: a subanalysis of the phase III, randomized ARCH study. Osteoporos Int. April 2020;31(4):677-685.
2020	Bassatne A, Harb H, Jaafar B, Romanos J, Ammar W, Fuleihan GE-H. Disease burden of osteoporosis and other non-communicable diseases in Lebanon. Osteoporos Int. September 2020;31(9):1769-1777.
2020	Kanis JA, Cooper C, Dawson-Hughes B, Harvey NC, Johansson H, Lorentzon M, McCloskey EV, Reginster J-Y, Rizzoli R; International Osteoporosis Foundation. FRAX and ethnicity. Osteoporos Int. November 2020;31(11):2063-2067.
2020	Lewiecki EM, Wright NC, Singer AJ. Racial disparities, FRAX, and the care of patients with osteoporosis. Osteoporos Int. November 2020;31(11):2069-2071.
2020	Lewiecki EM, Binkley N, Clark P, Kim S, Leslie WD, Morin SN. Core principles for fracture prevention: North American Consensus from the National Osteoporosis Foundation, Osteoporosis Canada, and Academia Nacional de Medicina de Mexico. Osteoporos Int. November 2020;31(11):2073-2076.
2020	Adami G, Gatti D, Rossini M, Orsolini G, Pollastri F, Bertoldo E, Viapiana O, Bertoldo F, Giollo A, Fassio A. Risk of fragility fractures in obesity and diabetes: a retrospective analysis on a nation-wide cohort. Osteoporos Int. November 2020;31(11):2113-2122.
2021	Burden AM, Tanaka Y, Xu L, Ha Y-C, McCloskey E, Cummings SR, Glüer CC. Osteoporosis case ascertainment strategies in European and Asian countries: a comparative review. Osteoporos Int. May 2021;32(5):817-829.
2018	Enns-Bray WS. Identifying Individuals Predisposed to Hip Fracture [PhD thesis]. Swiss Federal Institute of Technology Zürich; 2018.
2019	Fleps I. Assessing the Risk of Hip Fracture: Subject-Specific Dynamic Models for the Simulation of Sideways Fall Impact [PhD thesis]. Swiss Federal Institute of Technology Zürich; 2019.
2014	Bradke BS. The Role of Cortical and Cancellous Bone Quality on Vertebral Fragility [PhD thesis]. Troy, NY: Rensselaer Polytechnic Institute; April 2014.
2022	Tice MJL. Loss and Modulation of Bone Matrix and Fragility During Diabetes Mellitus [PhD thesis]. Troy, NY: Rensselaer Polytechnic Institute; May 2022.
2013	Rubin KH. The Use of Risk Assessment Tools in the Clinical Management of Osteoporosis [PhD thesis]. University of Southern Denmark (SDU); July 2013.
2022	Laskou F. Understanding the Relationship Between Muscle and Bone in Older Adults: An Investigation of Two Cohorts [MD thesis]. University of Southampton; November 28, 2022.
2017	Levine IC. The Effects of Body Composition and Body Configuration on Impact Dynamics During Lateral Falls: Insights from in-Vivo, in-Vitro, and in-Silico Approaches [PhD thesis]. University of Waterloo; 2017.
2016	Manhard MK. Advancements of MRI Measurements of Bound and Pore Water Concentration of Cortical Bone for Evaluation of Fracture Risk [PhD thesis]. Nashville, TN: Vanderbilt University; August 2016.